Cutaneous Metastasis of Giant Cell-Rich Osteosarcoma

Choo, Ji Yoon; Lee, Ji Hyun; Lee, Jun Young; Park, Young Min

doi:10.5021/ad.2016.28.2.247

Cited by 5 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, 66% of CSM were noted over the trunk and ventrum, while the head and neck region were affected in 24% of cases. In humans, skin metastasis from OSA seems to most commonly affect the scalp . No site of predilection was apparent from the 6 cases previously reported in dogs, as CSM were noted throughout the entire body; over the thigh, hip, larynx, and tarsus; or interscapular and dorsal lumbar areas .…”

Section: Discussionmentioning

confidence: 88%

“…In our study population, the median CMetFI was over 5 months (160 days), but the CMetFI varied considerably between dogs, from 0 days up to 18 months (542 days). In humans, the time between the initial diagnosis of OSA and the detection of skin metastasis is also quite variable and ranges from 0 days to 24 years . In the 6 previously reported dogs, the CMetFI ranged from 0 days to 40 months .…”

Section: Discussionmentioning

confidence: 94%

“…A majority of humans affected with CSM from OSA are reported to have had other sites of metastasis (lung, bone, lymph nodes, pleura, liver, central nervous system, etc.) detected concurrently or within 6 months . Considering the 6 previously reported cases of CSM from OSA in dogs, 2 had CSM diagnosed at the initial diagnosis with no other concomitant metastatic sites, and 4 had CSM diagnosed 1, 6, 7, and 19 months after the first metastatic event (pulmonary in all cases).…”

Section: Discussionmentioning

confidence: 95%

“…The subcutaneous tissue seemed to be affected more frequently than the dermis. On the other hand, most reports in people of CSM from OSA describe dermal, firm, erythematous, and painful lesions . Of the 6 reported cases in dogs, 4 cases had subcutaneous masses and 2 had dermal masses .…”

Section: Discussionmentioning

confidence: 95%

“…Most dogs were euthanized due to progressive metastasis to the lungs or bone, or noted general decline. The prognosis for humans with CSM from OSA is also guarded due to rapid progression of the disease and poor response to conventional chemotherapies …”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Cutaneous and subcutaneous metastasis of appendicular osteosarcoma in dogs: 20 cases

Parachini‐Winter

Curran

Pellin

et al. 2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Metastasis of appendicular osteosarcoma is most common to the lungs and is generally considered a terminal event in dogs. Behavior and prognosis associated with cutaneous or subcutaneous metastases (CSM) is poorly defined. Objective Describe the population and gather prognostic information regarding appendicular osteosarcoma with CSM in dogs. Animals Twenty dogs with appendicular osteosarcoma and CSM. Methods Retrospective case series. Medical records were searched to identify dogs diagnosed with appendicular osteosarcoma that developed CSM. Demographic data, order of metastatic events, and CSM clinical features were evaluated. Kaplan‐Meier survival curves were constructed and log‐rank tests were used to compare survival between groups of dogs. Results In 19 dogs (95%), CSM was an incidental finding. Seventeen dogs (85%) developed pulmonary metastasis, and 1 dog (5%) developed bone metastasis. No other metastatic sites were detected before euthanasia. The median CSM‐free interval and CSM survival time were 160 days (range: 0‐542 days) and 55 days (range: 5‐336 days), respectively. The median CSM survival time was significantly longer for dogs treated with surgery and chemotherapy (94 days) or chemotherapy only (64 days) than for dogs that did not receive these treatments (11 days) (P = .002 and P = .03, respectively). No other factors were associated with survival after diagnosis of CSM. Conclusion and Clinical Importance The skin or subcutaneous tissue can be the first osteosarcoma metastatic site detected. After CSM diagnosis, the prognosis is grave with median survival <2 months. Although this finding could have been biased by case selection, treatment with surgery and chemotherapy may improve outcome.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Cutaneous and subcutaneous metastasis of appendicular osteosarcoma in dogs: 20 cases

Parachini‐Winter

Curran

Pellin

et al. 2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

Giant cell‐rich osteosarcoma: A match pair analysis of 11 new cases and literature review of 56 patients

Karczewski

Gonzalez

Bedi

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

BackgroundLimited remains known on giant cell‐rich osteosarcoma (GCRO) with current studies being case reports or smaller series. This investigation compared GCRO and conventional osteoblastic osteosarcoma (OOS) with regard to demographics and survival.MethodsAn institutional tumor registry was used to identify 11 patients (six males) treated for GCRO. Mean age was 43 years. Staging showed American Joint Committee on Cancer (AJCC) stages IIA in four and IIB in seven patients. Mean follow‐up was 14 years. Study initiatives were: (1) Comparison of demographics between GCRO and 167 OOS from our institutional registry, (2) Differences in survival between GCRO and 33 OOS case controls (based on sex and AJCC stage), as well as 10 OOS using an age‐based propensity match, and (3) Summary of all GCRO cases reported in the literature.Results(1) Sex (p = 0.53), grading (p = 0.56), AJCC stage (p = 0.42), and chemotherapeutic response rate (p = 0.67) did not differ between groups. Age was significantly increased in GCRO (p = 0.001). (2) Case–control and propensity‐matched groups revealed no difference in disease‐free survival, local recurrence, and distant disease‐free survival at 2 years (p > 0.05). (3) Mean age of 56 patients (50% males) reported in the literature was 26 years. After merging with our 11 cases, the 2‐year disease‐free survival was 66%.ConclusionsGCRO remains a rare disease with high short‐term mortality. Although affecting older patients more than conventional osteosarcoma, GCRO should not be viewed as a predictor of survival compared to OOS.

show abstract